These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28255905)

  • 1. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
    Morjaria JB; Rigby A; Morice AH
    Lung; 2017 Jun; 195(3):281-288. PubMed ID: 28255905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
    Tashkin DP; Miravitlles M; Celli BR; Metzdorf N; Mueller A; Halpin DMG; Anzueto A
    Respir Res; 2018 Oct; 19(1):196. PubMed ID: 30290801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL; Lin CH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2341-2348. PubMed ID: 27703344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related.
    Koehorst-Ter Huurne K; Kort S; van der Palen J; van Beurden WJ; Movig KL; van der Valk P; Brusse-Keizer M
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1679-88. PubMed ID: 27555758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan.
    Hirano R; Fujita M; Matsumoto T; On R; Watanabe K
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3503-3509. PubMed ID: 30498340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD.
    Yamauchi Y; Yasunaga H; Hasegawa W; Sakamoto Y; Takeshima H; Jo T; Matsui H; Fushimi K; Nagase T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1403-11. PubMed ID: 27382276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study.
    Wang CY; Lai CC; Yang WC; Lin CC; Chen L; Wang HC; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2775-2783. PubMed ID: 27877031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
    Postma DS; Roche N; Colice G; Israel E; Martin RJ; van Aalderen WM; Grigg J; Burden A; Hillyer EV; von Ziegenweidt J; Gopalan G; Price D
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1163-86. PubMed ID: 25378918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
    Vogelmeier C; Worth H; Buhl R; Criée CP; Lossi NS; Mailänder C; Kardos P
    Int J Chron Obstruct Pulmon Dis; 2017; 12():487-494. PubMed ID: 28203072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD.
    Janson C; Stratelis G; Miller-Larsson A; Harrison TW; Larsson K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3055-3064. PubMed ID: 29089754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
    Calverley PMA; Stockley RA; Seemungal TAR; Hagan G; Willits LR; Riley JH; Wedzicha JA;
    Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.
    Yang M; Du Y; Chen H; Jiang D; Xu Z
    Int Immunopharmacol; 2019 Dec; 77():105950. PubMed ID: 31629940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.
    Short PM; Williamson PA; Elder DHJ; Lipworth SIW; Schembri S; Lipworth BJ
    Chest; 2012 Jan; 141(1):81-86. PubMed ID: 21799028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia.
    Cheng SL; Su KC; Wang HC; Perng DW; Yang PC
    Drug Des Devel Ther; 2014; 8():601-7. PubMed ID: 24920884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease.
    Rodriguez-Roisin R; Tetzlaff K; Watz H; Wouters EF; Disse B; Finnigan H; Magnussen H; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1973-81. PubMed ID: 27578972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled corticosteroids, blood eosinophils, and FEV
    Whittaker HR; Müllerova H; Jarvis D; Barnes NC; Jones PW; Compton CH; Kiddle SJ; Quint JK
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1063-1073. PubMed ID: 31213788
    [No Abstract]   [Full Text] [Related]  

  • 19. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.